RHHVF ROCHE HOLDINGS AG
- 317.268
- +4.678+1.50%
ROCHE HOLDINGS AG News
Barclays Maintains ROCHE HOLDINGS AG(RHHVF.US) With Hold Rating, Cuts Target Price to $317.72
UBS Maintains ROCHE HOLDINGS AG(RHHVF.US) With Hold Rating, Raises Target Price to $312.65
Deutsche Bank Maintains ROCHE HOLDINGS AG(RHHVF.US) With Sell Rating, Raises Target Price to $289.07
DZ BANK AG Maintains ROCHE HOLDINGS AG(RHHVF.US) With Buy Rating
J.P. Morgan Maintains ROCHE HOLDINGS AG(RHHVF.US) With Sell Rating, Raises Target Price to $254.38
Deutsche Bank Maintains ROCHE HOLDINGS AG(RHHVF.US) With Sell Rating, Raises Target Price to $271.73
UBS Maintains ROCHE HOLDINGS AG(RHHVF.US) With Hold Rating, Cuts Target Price to $311.8
Barclays Maintains ROCHE HOLDINGS AG(RHHVF.US) With Hold Rating, Cuts Target Price to $319.12
A Quick Look at Today's Ratings for ROCHE HOLDINGS AG(RHHVF.US), With a Forecast Between $255.33 to $336.57
Deutsche Bank Maintains ROCHE HOLDINGS AG(RHHVF.US) With Sell Rating, Maintains Target Price $274.14
J.P. Morgan Maintains ROCHE HOLDINGS AG(RHHVF.US) With Sell Rating, Raises Target Price to $256.64
Genentech's Evrysdi Two-Year Data Shows Promising Results In Spinal Muscular Atrophy, Most Children Treated Early Reach Key Mobility Milestones
Goldman Sachs Maintains ROCHE HOLDINGS AG(RHHVF.US) With Sell Rating, Raises Target Price to $305.17
UBS Maintains ROCHE HOLDINGS AG(RHHVF.US) With Hold Rating, Cuts Target Price to $316.91
Barclays Maintains ROCHE HOLDINGS AG(RHHVF.US) With Hold Rating, Cuts Target Price to $324.44
Stifel Maintains ROCHE HOLDINGS AG(RHHVF.US) With Hold Rating, Cuts Target Price to $371.64
J.P. Morgan Maintains ROCHE HOLDINGS AG(RHHVF.US) With Sell Rating, Cuts Target Price to $260.42
Goldman Sachs Maintains ROCHE HOLDINGS AG(RHHVF.US) With Sell Rating, Raises Target Price to $295.25
J.P. Morgan Maintains ROCHE HOLDINGS AG(RHHVF.US) With Sell Rating, Raises Target Price to $259.82
Roche Narrows Pipeline to 11 Disease Areas Amidst Weight Loss Push - WSJ
Analysis
Price Target
No Data
No Data